Eli Lilly Finalizes Acquisition Agreement with Morphic for $3.2 Billion

Eli Lilly and Company (LLY) on July 8, 2024, entered a definitive merger agreement to acquire Morphic Holding, Inc. (MORF) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for types of inflammatory bowel diseases.

Please subscribe for free or login to your InsideArbitrage account to access this article.